CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Zhengye Biotechnology Holding Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Zhengye Biotechnology Holding Ltd
JILIN, JLN  132101  China Ticker: ZYBTZYBT
Business Summary
Zhengye Biotechnology Holding Ltd is a company mainly engaged in the research, development, manufacturing and sales of veterinary vaccines, with an emphasis on vaccines for livestock. The Company markets a diverse range of vaccines, including vaccines for swine, cattle, goats, sheep, poultry, and dogs. The Company owns about 44 veterinary vaccines in its product portfolio, which cover veterinary vaccines for livestock, including monovalent vaccine, polyvalent vaccine, combined vaccine and combined and polyvalent vaccine. The Company also engages in vaccines for treating livestock. The Company mainly conducts its business in the domestic market. The Company mainly conducts its business in the domestic and overseas market.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023YesYes---

Industries
SIC Code Description
2836 Biological products, except diagnostic substances
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board ZhenfaHan 70 5/1/2023 3/1/2023
Chief Executive Officer SonglinSong 48 5/1/2023 5/1/2023
Chief Financial Officer PingWang 43 5/1/2023 5/1/2023
7 additional Officers and Directors records available in full report.

General Information
Number of Employees: 275 (As of 4/30/2024)
Outstanding Shares: 46,916,376 (As of 12/31/2023)
Stock Exchange: NASD


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, January 20, 2025